Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

Inclusion Criteria: * Patients ≥18 years with RA, RARS, RAEB (blasts \<10%) * Hb\< 10g/dl \> of 2 months or transfused since less 2 months * Hb\<12g/dl \> of 2 months and thrombocytopenia defined by platelets \< 50 000/mm3, or neutropenia\<10 000mm3 * For women of child bearing age, necessity of contraception during all the duration of the study Exclusion Criteria: * Patient with lung disease, cardiac, neurological, gastro-intestinal or genito - urinary disorders not connected to genito -urinary not connected to myelodysplasia * Patient having received intensive chemotherapy in the 3 months before inclusion in the protocol * RAEBt * RAEB \>10% blasts * Treatment with rHu-Epo, darbepoetin ou rHu-GCSF , 2 months before inclusion * Patient presenting an iron , B12 vitamin or folic acid uncorrected deficit * CMML * Uncontrolled systemic hypertension * creatinine clearance \< 300 µM/L * Pregnant patient or in period of lactation * Life expectancy \< 6 months